Acinetobacter Pneumonia Therapeutics Market Share

North America Market Analysis

North America in acinetobacter pneumonia therapeutics market is set to capture over 46.1% revenue share by 2037. The market’s growth is attributed to robust healthcare infrastructure in the region and an increasing diagnosis of Acinetobacter pneumonia cases. The market also benefits from a robust regulatory ecosystem that facilitates clinical trials and approvals of new antibiotic formulations to treat bacterial pneumonia. The presence of leading pharmaceutical companies and research institutes in North America plays a role in bolstering the market’s growth.

The U.S. holds the largest acinetobacter pneumonia therapeutics market share in North America. The market’s growth in the country is attributed to increasing diagnosis of bacterial pneumonia cases and the demands for novel solutions to manage infection. In December 2020, the morbidity and mortality weekly report by the Centers for Disease Control and Prevention stated an increase in hospital acquired carbapenem resistant Acinetobacter baumannii infection during a surge in COVID-19. There’s a growing focus in the country for early vaccination to generate an immune response before exposure to Acinetobacter baumannii.

Additionally, a robust healthcare system in the country facilitates key players to invest in research for antibiotic formulations for Acinetobacter pneumonia. For instance, in March 2021, the Department of Veteran Affairs (VA) launched the National Organization for NV-HAP Prevention (NOHAP) as an organized effort to assist in the prevention of hospital acquired pneumonia in hospitals across U.S.

Canada is poised to increase its revenue share in North America during the forecast period. The market’s growth is attributed to increased government investments in healthcare and drug research. For instance, in December 2023, the government of Canada announced the creation of the Canadian Drug Agency to make the drug system more sustainable and improve access of citizens to prescription drugs. Additionally, a robust ecosystem favorable to research is boosting the market’s growth. For instance, in May 2023, researchers from Hamilton University leveraged artificial intelligence (AI) to find treatment for a bacteria superbug.

APAC Market Analysis

The Asia Pacific acinetobacter pneumonia therapeutics market is poised to register the fastest growth by the end of the forecast period. The acinetobacter pneumonia therapeutics market growth is attributed to the rising prevalence of hospital acquired pneumonia (HAP) and ventilator-acquired pneumonia (VAP). For instance, in 2022, a study published in Science Direct assessed the factors predicting non-ventilated hospital-acquired pneumonia and found HAP results in almost 20% infections in hospitals, with more than two-thirds of patients not using mechanical ventilation. Additionally, the report indicated incidences of non-ventilated hospital acquired pneumonia (NVHAP) increasing and are associated with higher mortality rates.

China is leading the acinetobacter pneumonia therapeutics market share in Asia Pacific owing to rising awareness on combating the threat of multi drug resistant-Acinetobacter strains. Approval of new novelty therapeutics is set to boost the market’s continued growth in the country. In January 2019, a study published in the National Library of Medicine that reported a clinical HAP survey in 13 large hospitals in China reported a 1.4% incidence of HAP in ICUs, 15.3% in RICUs, and 0.9% in general wards. The percentage is likely to increase by the end of the forecast period owing to an aging population and longer hospital stays, increasing susceptibility to Acinetobacter baumannii.

 The demand for advanced therapeutics is rising in the country, and key market players are positioned to cater to demands. For instance, in May 2024, Zai Lab and Innoviva Specialty Therapeutics announced approval by China’s National Medical Products Administration (NMPA) for the new drug application for Xacduro.

India is projected to increase acinetobacter pneumonia therapeutics market share in Asia Pacific with a rapid growth curve by the end of the forecast period. The large-population in the country also increases footfalls in hospitals and other specialty clinics. The percentage of patients requiring ICU visits also increases due to the large population. This increases the percentage of patients vulnerable to various cases of hospital acquired pneumonia.

The government efforts in ramping up research to combat antimicrobial resistance creates new opportunities for pharmaceutical companies to develop novel therapeutics. For instance, in September 2023, Orchid Pharma, a subsidiary of Dhanuka Labs, announced that it had gained a sublicense to manufacture cefiderocol.